Abstract
Fatty acid synthase (FASN), catalyzing the de novo synthesis of fatty acids, is known to be deregulated in several cancers. Inhibition of this enzyme reduces tumor cell proliferation. Unfortunately, adverse effects and chemical instability prevent the in vivo use of the best-known inhibitors, Cerulenin and C75. Orlistat, a drug used for obesity treatment, is also considered as a potential FASN inhibitor, but its impact on glioma cell biology has not yet been described. In this study, we analyzed FASN expression in human glioma samples and primary glioblastoma cell cultures and the effects of FASN inhibition with Orlistat, Cerulenin and C75. Immunohistochemistry followed by densitometric analysis of 20 glioma samples revealed overexpression of FASN that correlated with the WHO tumor grade. Treatment of glioblastoma cells with these inhibitors resulted in a significant, dose-dependent reduction in tumor cell viability and fatty acid synthesis. Compared to Cerulenin and C75, Orlistat was a more potent inhibitor in cell cultures and cell lines. In LN229, cell-growth was reduced by 63.9 ± 8.7 % after 48 h and 200 µM Orlistat compared to controls; in LT68, the reduction in cell growth was 76.3 ± 23.7 %. Nuclear fragmentation assay and Western blotting analysis after targeting FASN with Orlistat demonstrated autophagy and apoptosis. Organotypic slice cultures treated with Orlistat showed reduced proliferation after Ki67 staining and increased caspase-3 cleavage. Our results suggest that FASN may be a therapeutic target in malignant gliomas and identify Orlistat as a possible anti-tumor drug in this setting.
Similar content being viewed by others
References
Ohgaki H, Kleihues P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64:479–489
Preusser M, de Ribaupierre S, Wohrer A, Erridge SC, Hegi M, Weller M, Stupp R (2011) Current concepts and management of glioblastoma. Ann Neurol 70:9–21. doi:10.1002/ana.22425
Kuhajda FP (2006) Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 66:5977–5980. doi:10.1158/0008-5472.CAN-05-4673
Menendez JA, Lupu R (2007) Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7:763–777. doi:10.1038/nrc2222
Zhao W, Kridel S, Thorburn A, Kooshki M, Little J, Hebbar S, Robbins M (2006) Fatty acid synthase: a novel target for antiglioma therapy. Br J Cancer 95:869–878. doi:10.1038/sj.bjc.6603350
Guo D, Prins RM, Dang J, Kuga D, Iwanami A, Soto H, Lin KY, Huang TT, Akhavan D, Hock MB, Zhu S, Kofman AA, Bensinger SJ, Yong WH, Vinters HV, Horvath S, Watson AD, Kuhn JG, Robins HI, Mehta MP, Wen PY, DeAngelis LM, Prados MD, Mellinghoff IK, Cloughesy TF, Mischel PS (2009) EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal 2: ra82 doi:10.1126/scisignal.2000446
Tao BB, He H, Shi XH, Wang CL, Li WQ, Li B, Dong Y, Hu GH, Hou LJ, Luo C, Chen JX, Chen HR, Yu YH, Sun QF, Lu YC (2013) Up-regulation of USP2a and FASN in gliomas correlates strongly with glioma grade. J Clin Neurosci 20:717–720. doi:10.1016/j.jocn.2012.03.050
Maier T, Leibundgut M, Boehringer D, Ban N (2010) Structure and function of eukaryotic fatty acid synthases. Q Rev Biophys 43:373–422. doi:10.1017/S0033583510000156
Kusakabe T, Maeda M, Hoshi N, Sugino T, Watanabe K, Fukuda T, Suzuki T (2000) Fatty acid synthase is expressed mainly in adult hormone-sensitive cells or cells with high lipid metabolism and in proliferating fetal cells. J Histochem Cytochem 48:613–622
Kersten S (2001) Mechanisms of nutritional and hormonal regulation of lipogenesis. EMBO Rep 2:282–286. doi:10.1093/embo-reports/kve071
Kim JB, Sarraf P, Wright M, Yao KM, Mueller E, Solanes G, Lowell BB, Spiegelman BM (1998) Nutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1/SREBP1. J Clin Invest 101:1–9. doi:10.1172/JCI1411
Van de Sande T, De Schrijver E, Heyns W, Verhoeven G, Swinnen JV (2002) Role of the phosphatidylinositol 3′-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells. Cancer Res 62:642–646
Yang YA, Han WF, Morin PJ, Chrest FJ, Pizer ES (2002) Activation of fatty acid synthesis during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Exp Cell Res 279:80–90
Rossi S, Graner E, Febbo P, Weinstein L, Bhattacharya N, Onody T, Bubley G, Balk S, Loda M (2003) Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res 1:707–715
Cerne D, Zitnik IP, Sok M (2010) Increased fatty acid synthase activity in non-small cell lung cancer tissue is a weaker predictor of shorter patient survival than increased lipoprotein lipase activity. Arch Med Res 41:405–409. doi:10.1016/j.arcmed.2010.08.007
Ogino S, Nosho K, Meyerhardt JA, Kirkner GJ, Chan AT, Kawasaki T, Giovannucci EL, Loda M, Fuchs CS (2008) Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol 26:5713–5720. doi:10.1200/JCO.2008.18.2675
Kusakabe T, Nashimoto A, Honma K, Suzuki T (2002) Fatty acid synthase is highly expressed in carcinoma, adenoma and in regenerative epithelium and intestinal metaplasia of the stomach. Histopathology 40:71–79
Jiang B, Li EH, Lu YY, Jiang Q, Cui D, Jing YF, Xia SJ (2012) Inhibition of fatty-acid synthase suppresses P-AKT and induces apoptosis in bladder cancer. Urology 80: 484 e489-415 doi:10.1016/j.urology.2012.02.046
Makino K, Nakamura H, Hide T, Yano S, Kuroda J, Iyama K, Kuratsu J (2012) Fatty acid synthase is a predictive marker for aggressiveness in meningiomas. J Neurooncol 109:399–404. doi:10.1007/s11060-012-0907-3
Loftus TM, Jaworsky DE, Frehywot GL, Townsend CA, Ronnett GV, Lane MD, Kuhajda FP (2000) Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science 288:2379–2381
Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW (2004) Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 64:2070–2075
Westphal M, Nausch H, Zirkel D (1996) Cell culture of human brain tumors on extracellular matrices : methodology and biological applications. Methods Mol Med 2:81–99. doi:10.1385/0-89603-335-X:81
Haase D, Schmidl S, Ewald C, Kalff R, Huebner C, Firsching R, Keilhoff G, Evert M, Paulus W, Gutmann DH, Lal A, Mawrin C (2010) Fatty acid synthase as a novel target for meningioma therapy. Neuro Oncol 12:844–854. doi:10.1093/neuonc/noq004
Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45
Zecchin KG, Rossato FA, Raposo HF, Melo DR, Alberici LC, Oliveira HC, Castilho RF, Coletta RD, Vercesi AE, Graner E (2011) Inhibition of fatty acid synthase in melanoma cells activates the intrinsic pathway of apoptosis. Lab Invest 91:232–240. doi:10.1038/labinvest.2010.157
Porstmann T, Griffiths B, Chung YL, Delpuech O, Griffiths JR, Downward J, Schulze A (2005) PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene 24:6465–6481. doi:10.1038/sj.onc.1208802
Wang HQ, Altomare DA, Skele KL, Poulikakos PI, Kuhajda FP, Di Cristofano A, Testa JR (2005) Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene 24:3574–3582. doi:10.1038/sj.onc.1208463
Alo PL, Visca P, Marci A, Mangoni A, Botti C, Di Tondo U (1996) Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer 77:474–482. doi:10.1002/(SICI)1097-0142(19960201)77:3<474:AID-CNCR8>3.0.CO;2-K
Piyathilake CJ, Frost AR, Manne U, Bell WC, Weiss H, Heimburger DC, Grizzle WE (2000) The expression of fatty acid synthase (FASE) is an early event in the development and progression of squamous cell carcinoma of the lung. Hum Pathol 31:1068–1073. doi:10.1053/hupa.2000.9842
Liu H, Liu JY, Wu X, Zhang JT (2010) Biochemistry, molecular biology, and pharmacology of fatty acid synthase, an emerging therapeutic target and diagnosis/prognosis marker. Int J Biochem Mol Biol 1:69–89
Knowles LM, Yang C, Osterman A, Smith JW (2008) Inhibition of fatty-acid synthase induces caspase-8-mediated tumor cell apoptosis by up-regulating DDIT4. J Biol Chem 283:31378–31384. doi:10.1074/jbc.M803384200
Kuhajda FP, Pizer ES, Li JN, Mani NS, Frehywot GL, Townsend CA (2000) Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci USA 97:3450–3454. doi:10.1073/pnas.050582897
Vance D, Goldberg I, Mitsuhashi O, Bloch K (1972) Inhibition of fatty acid synthetases by the antibiotic cerulenin. Biochem Biophys Res Commun 48:649–656
Lookene A, Skottova N, Olivecrona G (1994) Interactions of lipoprotein lipase with the active-site inhibitor tetrahydrolipstatin (Orlistat). Eur J Biochem 222:395–403
Browne CD, Hindmarsh EJ, Smith JW (2006) Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor. Faseb J 20:2027–2035. doi:10.1096/fj.05-5404com
Little JL, Wheeler FB, Fels DR, Koumenis C, Kridel SJ (2007) Inhibition of fatty acid synthase induces endoplasmic reticulum stress in tumor cells. Cancer Res 67:1262–1269. doi:10.1158/0008-5472.CAN-06-1794
Swinnen JV, Van Veldhoven PP, Timmermans L, De Schrijver E, Brusselmans K, Vanderhoydonc F, Van de Sande T, Heemers H, Heyns W, Verhoeven G (2003) Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. Biochem Biophys Res Commun 302:898–903
Grunt TW, Wagner R, Grusch M, Berger W, Singer CF, Marian B, Zielinski CC, Lupu R (2009) Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells. Biochem Biophys Res Commun 385:454–459. doi:10.1016/j.bbrc.2009.05.085
Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF, Agarwalla PK, Chheda MG, Campos B, Wang A, Brennan C, Ligon KL, Furnari F, Cavenee WK, Depinho RA, Chin L, Hahn WC (2012) Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 26:756–784. doi:10.1101/gad.187922.112
Hill MM, Feng J, Hemmings BA (2002) Identification of a plasma membrane Raft-associated PKB Ser473 kinase activity that is distinct from ILK and PDK1. Curr Biol 12:1251–1255
Zhuang L, Lin J, Lu ML, Solomon KR, Freeman MR (2002) Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. Cancer Res 62:2227–2231
Kant S, Kumar A, Singh SM (2014) Tumor growth retardation and chemosensitizing action of fatty acid synthase inhibitor orlistat on T cell lymphoma: implication of reconstituted tumor microenvironment and multidrug resistance phenotype. Biochim Biophys Acta 1840:294–302. doi:10.1016/j.bbagen.2013.09.020
Paumen MB, Ishida Y, Han H, Muramatsu M, Eguchi Y, Tsujimoto Y, Honjo T (1997) Direct interaction of the mitochondrial membrane protein carnitine palmitoyltransferase I with Bcl-2. Biochem Biophys Res Commun 231:523–525. doi:10.1006/bbrc.1997.6089
Ogretmen B, Hannun YA (2004) Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 4:604–616. doi:10.1038/nrc1411
Knowles LM, Smith JW (2007) Genome-wide changes accompanying knockdown of fatty acid synthase in breast cancer. BMC Genom 8:168. doi:10.1186/1471-2164-8-168
Tomek K, Wagner R, Varga F, Singer CF, Karlic H, Grunt TW (2011) Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer. Mol Cancer Res 9:1767–1779. doi:10.1158/1541-7786.MCR-10-0467
Conflict of interest
The authors declare that they have no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Grube, S., Dünisch, P., Freitag, D. et al. Overexpression of fatty acid synthase in human gliomas correlates with the WHO tumor grade and inhibition with Orlistat reduces cell viability and triggers apoptosis. J Neurooncol 118, 277–287 (2014). https://doi.org/10.1007/s11060-014-1452-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-014-1452-z